<DOC>
	<DOCNO>NCT02693366</DOCNO>
	<brief_summary>The purpose study analyze safety , renal function , metabolic disorder quality life data patient focal segmental glomerulosclerosis treat endovascular infusion bone marrow derive mononuclear cell .</brief_summary>
	<brief_title>Stem Cell Therapy Patients With Focal Segmental Glomerulosclerosis</brief_title>
	<detailed_description>Will study five patient progressive chronic kidney disease estimate clearance 40 20 ml / min . Patients follow clinical laboratory examination 3 month prior procedure . These previous result serve control comparison second time patient receive treatment stem cell subsequently follow 9 month total one year clinical follow-up . Bone marrow aspiration subsequent cell preparation accomplish day endovascular infusion autologous Bone Marrow derive Mononuclear stem cell ( BMDMCs ) renal artery . Collection perform spinal anesthesia light sedation , puncture repeat aspiration posterior iliac crest region . A total 80 mL bone marrow aspirate collect patient , removal bone fatty residue , mononuclear cell isolate Ficoll-Paque Plus ( Amersham Biosciences , São Paulo , Brazil ) .For patient , 2×107 cell label 99mTc . Briefly , 500 μl sterile SnCl2 solution add cell mixture incubate room temperature 10 min . Forty-five millicurie ( mCi ) 99mTc added incubation continue another 10 min . After centrifugation ( 500×g 5 min ) , supernatant remove cell wash saline solution . The pellet also resuspend saline solution . Viability label cell assess trypan blue exclusion test , estimate great 93 % cases.The labeling efficiency ( % ) calculate activity pellet divide sum radioactivity pellet plus supernatant estimate great 90 % case . After collection stem cell , patient submit puncture femoral artery use Seldinger technique local anesthesia , follow catheterization ostium renal artery minimum use nonionic iodinate contrast . With rout diagnostic catheter guide , solution number 30 100 million dissolve plasma cell divide injected two renal artery . The infusion volume 5 ml kidney . Whole body planar scan perform 2 24h infusion determine migration cell viability . The patient remain hospitalized 48 hour clinical monitoring collection laboratorial test .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Patients diagnosis primary focal segmental glomerulosclerosis previously treat corticosteroid immunosuppressive drug reach satisfactory answer . Will also consider candidate patient perform late diagnosis therefore clinical indication perform therapy corticosteroid immunosuppressant . In case , show irreversible loss renal function filtration rate 40 20 ml/min . Patient use classical nephroprotective medication : angiotensinconverting enzyme inhibitor angiotensinreceptor blocker , . Acute urinary tract infection ; Urinary infection tuberculosis bacillus fungi ; Patients poorly anatomical formation urinary tract , polycystic kidney disease congenital acquire kidney disease . Blood pressure great 160 mm Hg systolic 100 mmHg diastolic , measurement take last 3 outpatient visit ; Who perform examination iodinate contrast last 3 month Use potentially nephrotoxic drug ; Use corticosteroid therapy immunosuppressive dos 0.3 mg/kg/day Inability obtain vascular access endovascular procedure Sepsis ( define accord Society Critical Care Medicine , American College Chest Physicians , 1992 ) ; Malignancies Autoimmune disorder , Neurodegenerative diseases ; Acute heart failure decompensated ; Primary hematologic disease ; Osteopathies reflect increase risk spinal puncture ; Coagulopathies ; Liver failure ; History stroke myocardial infarction last 6 month ; Pregnancy breastfeeding ; History serology chronic infectious disease , include HIV , Hepatitis C virus , Hepatitis B virus Participation another clinical trial last year Cognitive impairment understand procedure Prolonged travel plan domicile change state generate unable attend followup visit ; Any clinically significant active disease opinion principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>bone marrow cell , stem cell , cell therapy</keyword>
	<keyword>Glomerulosclerosis , Focal Segmental</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
</DOC>